Multi-event January 2020 FDA Recall Drug by Direct Rx

This Multi-event Class II drug recall was voluntarily initiated by Direct Rx on January 15, 2020 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed in FL, GA and the recall is currently terminated.

Reported Recall Events

D-0016-2021 TERMINATED D-0017-2021 TERMINATED

Recall Number: D-0016-2021

Reason for Recall
CGMP Deviations: Presence of NDMA impurity detected in product.
Initiated
01-15-2020
Reported
10-14-2020
Quantity
a) 54 bottles; b) 26 bottles

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
86498
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Direct Rx
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
FL, GA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
12-07-2020
Product Description About Product Description
Full technical description of the product.
Ranitidine 150 mg, a) 60 Tabs (NDC 61919-339-60); and b) 90 Tabs (NDC 61919-339-90) bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534

Batch or Lot Expiration Information

Lot# Lots: a) 09AU1911 Exp. 02/28/2022; b) 09SE1904 Exp. 03/31/2022

Recall Number: D-0017-2021

Reason for Recall
CGMP Deviations: Presence of NDMA impurity detected in product.
Initiated
01-15-2020
Reported
10-14-2020
Quantity
26 bottles

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
86498
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Direct Rx
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
FL, GA
Termination Date About Termination Date
Date that FDA officially terminated the recall.
12-07-2020
Product Description About Product Description
Full technical description of the product.
Ranitidine 300 mg, 30 Tabs bottles, Rx only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 NDC 61919-455-30

Batch or Lot Expiration Information

Lot# Lot: 29JA1915 Exp. 09/30/2021